Pharma
Ireland’s drug pricing rules harming sales, AstraZeneca says
Marketing arm of pharma giant says laws allowing pharmacists to substitute interchangeable medicine products is ‘negatively’ impacting trade
The Irish marketing arm of AstraZeneca, the pharmaceutical giant, has said Ireland’s rules around the pricing of drugs are “negatively” impacting its business.
In its 2022 accounts, AstraZeneca Pharmaceuticals Ireland cited the “ongoing impact” of reference pricing – which allows pharmacists to substitute interchangeable medicine products in some cases – as a negative impact on its business in Ireland.
It said the model, which was introduced to cut the amount of money the government was ...
